ACUTE CORONARY SYNDROMES Rivaroxaban reduces serious CV events without increasing fatal bleeding in patients with a recent ACS

摘要

Results of the ATLAS ACS2-TIMI51 trial were released at the 2011 AHA Scientific Sessions in Orlando, FL, and published in the New England Journal of Medicine in November. In patients with a recent acute coronary syndrome (ACS), long-term administration of low doses of rivaroxaban (a direct factor Xa inhibitor) was associated with reduced risk of major cardiovascular events with no increase in risk of fatal bleeding. Notably, though, major bleeding and intracranial hemorrhage were increased with rivaroxaban use.